DOCSLIB.ORG

Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2010 Securities Code: 4506 Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2010 I. Consolidated Financial Highlights 1 II. Consolidated Statements of Income 3 III. Consolidated Balance Sheets 6 IV. Consolidated Statements of Cash Flows 8 V. Quarterly Business Results 9 Ⅵ. Development Pipeline 10 Ⅶ. Profile of Major Products under Development 14 February 3, 2010 Dainippon Sumitomo Pharma Co., Ltd. - This document contains forward-looking statements based on management’s assumptions and beliefs in light of the information currently available, and involve risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including economic conditions. - Forecasts for the year ending March 31, 2010 include figures of the subsidiaries in America. All values are rounded. Therefore totals may not be consistent with aggregated figures. I. Consolidated Financial Highlights 1. Highlights of the Statements of Income (Billions of Yen) Nine Nine months ended Year Year ending 3/31/10 months 12/31/09 ended (Forecasts) ended 12/31/08 Change (%)3/31/09 Change (%) Net sales 201.9 203.8 0.9 264.0 295.0 11.7 Cost of sales 78.9 79.1 0.3 103.7 113.5 9.4 SG&A expenses 95.5 92.7 (2.9) 129.1 150.5 16.5 SG&A expenses less 57.2 57.0 (0.3) 76.3 97.0 27.1 R&D costs R&D costs 38.3 35.7 (6.9) 52.8 53.5 1.3 Operating income 27.5 32.0 16.1 31.2 31.0 (0.5) Ordinary income 28.4 31.8 11.8 31.4 29.0 (7.6) Net income 17.1 21.2 23.8 20.0 19.0 (4.9) Notes1: Cost of sales includes provision for (reversal of) reserve for sales returns. 2: Sumitomo Pharmaceuticals (Suzhou) Co.,Ltd. is newly added as a consolidated subsidiary from this fisacal year. 3: The results of the subsidiaries in America (Dainippon Sumitomo Pharma America Holdings, Inc. / Dainippon Sumitomo Pharma America, Inc. / Sepracor Inc.）are to be included in consolidated results for Q4. (No impact on profit for Q3) Earnings per share (yen) 43.00 53.24 50.30 47.82 Return on equity (ROE) 5.3% 6.4% 6.2% 5.8% ２．Valuations and accounting procedures by acquisition of Sepracor （Millions of dollar） Impact on Before After Accounting Valuation pretax income purchase price purchase price procedures (Forecasts for allocation allocation differences (Amortization) FY2009） － Amortization years by Patent rights 1,208 1,208 products 69 In-process R&D Capitalize － 57 57 － (Intangible Assets) (Amortize after approval) Inventories 67 146 79 Charge to cost of sales 40 Deferred tax liabilities － (489) (489) －－ (of the above) Other assets & 661 721 6 －－ liabilities (Net) Goodwill 26 864 838 Amortization for 20 years 9 Total 754 2,506 1,753 118 Notes: The above amounts of purchase price allocation are provisionary for the present. Patent rights include sales rights. -supplementary1- 3. Highlights of the Balance Sheets (Billions of Yen) As of As of 3/31/09 12/31/09 (B) - (A) (A) (B) Total assets 391.3 667.1 275.9 Net assets 324.5 338.6 14.1 Shareholders' equity 324.4 338.6 14.0 Shareholders' equity ratio 82.9% 50.8% 4. Capital Expenditures and Depreciation (Billions of Yen) Nine Nine months months Year ending Year ended ended ended (B) - (A) 3/31/10 Change 3/31/09 12/31/08 12/31/09 (Forecasts) (A) (B) Capital expenditures 8.7 3.9 (4.7) 10.6 11.0 0.4 (including intangible assets) Depreciation and amortization 7.9 7.8 (0.1) 10.7 12.0 1.3 Note: The above amounts don’t include impact by asset valuation associated with acquisition of Sepracor. - Major capital expenditure projects for the year ending March 31, 2010 Integration of product formulations development functions in Technology Research & Development Division : ¥0.90 billion (total budget: ¥0.90 billion, to be completed in April 2010) 5. Highlights of the Statements of Cash Flows (Billions of Yen) Nine months Nine months ended ended (B)-(A) 12/31/08 12/31/09 （A） （B） Net cash provided by operating activities 12.6 20.4 7.8 Net cash used in investing activities (23.9) (173.9) (149.9) Net cash used in financing activities (11.8) 169.8 181.6 Increase related to change in scope of － 1.5 1.5 consolidation Cash and cash equivalents at the end of period 33.2 67.2 34.0 -supplementary2- II. Consolidated Statements of Income 1. Statements of Income (Billions of Yen) （Positives） Nine Nine ・Sales growth of LONASEN months months ®、AVAPRO®、AmBisome® ended ended Change ・Increased sales of DS 12/31/08 12/31/09 (B)-(A) (%) Pharma Biomedical Co., Ltd. (A) (B) （Negatives） Net sales 201.9 203.8 1.8 0.9 ・Decreased sales of AMLODIN® due to the Overseas sales 14.7 16.1 1.4 9.2 influence of generics Cost of sales 78.9 79.1 0.2 0.3 ・Contribution of Sumitomo Gross profit 123.0 124.7 1.6 1.3 Pharamaceuticals (Suzhou) Co., Ltd. SG&A expenses 95.5 92.7 (2.8) (2.9) Labor costs 24.5 25.5 1.1 4.3 ・Cost of sales ratio Advertising and 39.1%⇒38.8% 3.8 3.0 (0.8) (21.2) promotion costs (Decrease in the influence of Sales promotion costs 8.0 8.1 0.0 0.4 the application of "Accounting Standard for Other costs 21.0 20.5 (0.5) (2.2) Measurement of SG&A expenses less R&D Inventories") 57.2 57.0 (0.2) (0.3) costs R&D costs 38.3 35.7 (2.6) (6.9) ・Efficient spending of R&D costs Operating income 27.5 32.0 4.4 16.1 ・Review of overseas Non-operating income 2.6 1.9 (0.7) development examination contents(lurasidone), Non-operating expenses 1.7 2.1 0.4 influence of Yen's Ordinary income 28.4 31.8 3.4 11.8 appreciation Income before income taxes 28.4 31.8 3.4 11.8 and minority interests Income taxes 11.3 10.6 (0.7) Minority interests in net income 0.0 0.0 (0.0) Net income 17.1 21.2 4.1 23.8 Note: Cost of sales includes provision for (reversal of) reserve for sales returns. 2. Segment Information (Billions of Yen) Nine months ended Nine months ended Year ending 3/31/10 Year ended 3/31/09 12/31/08 12/31/09 （Forecasts） Pharma Other Pharma Other Pharma Other Pharma Other Total Total Total Total ceuticals products ceuticals products ceuticals products ceuticals products Net sales 158.2 43.7 201.9 158.7 45.1 203.8 206.8 57.2 264.0 236.0 59.0 295.0 Operating 26.4 1.2 27.5 29.8 2.2 32.0 29.8 1.3 31.2 income -supplementary3- 3. Sales of Major Products (C): Figures in parentheses [ ] are forecasts released on October 29, 2009. Pharmaceuticals（Domestic） （Billions of Yen） Nine Nine Year ending months Brand name (Generic name) months Change (Ｂ)/(Ｃ) Year ended 3/31/10 ended ended 3/31/09 (Forecasts) Therapeutic indication 12/31/08 12/31/09 (%) (%) (C) (A) (B) AMLODIN® (amlodipine) Therapeutic agent for hypertension 46.1 41.6 (9.7) 82.4 57.9 [49.5] 50.5 and angina pectoris GASMOTIN® (mosapride citrate) 15.5 16.2 4.2 77.0 20.2 21.0 Gastroprokinetic PRORENAL® (limaprost alfadex) 11.4 12.1 6.0 78.2 14.8 15.5 Vasodilator MEROPEN® (meropenem) 11.5 11.6 0.9 83.7 14.8 13.9 Carbapenem antibiotic EBASTEL® (ebastine) 6.5 6.4 (1.1) 70.6 10.6 9.1 Long-acting Antiallergic LONASEN® (blonanserin) 2.4 4.7 93.6 72.7 3.4 6.5 Antipsychotic agent SUMIFERON® (interferon-α NAMALWA)) 4.7 4.5 (2.9) 75.8 6.0 6.0 Natural alpha interferon GROWJECT® (somatropin) 3.3 3.6 6.7 77.6 4.3 4.6 Growth hormone AmBisome® (amphotericin B) Therapeutic agent for systemic 2.3 3.1 31.4 71.3 3.1 4.3 fungal infection MELBIN® (metformin) 2.5 3.0 17.5 76.8 3.4 3.9 Oral hypoglycemic DOPS® (droxidopa) Noradrenaline-activating neural 3.0 2.8 (4.0) 79.1 3.8 3.6 function ameliorant EXCEGRAN® (zonisamide) 2.8 2.8 1.0 74.4 3.6 3.8 Antiepileptic GLIMICRON® (gliclazide) 2.8 2.6 (8.0) 76.0 3.6 3.4 Oral hypoglycemic AVAPRO® (irbesartan) Therapeutic agent for 1.4 2.4 76.9 61.0 1.5 4.0 hypertension QVARTM (beclomethasone dipropionate) 2.8 2.3 (17.7) 76.1 3.6 3.0 Inhaled steroid antiasthmatic ALMARL® (arotinolol) Therapeutic agent for hypertension, 2.4 2.2 (5.9) 77.0 3.0 2.9 angina pectoris and arrhythmia LULLAN® (perospirone) 2.2 2.0 (9.4) 75.1 2.8 2.7 Antipsychotic SEDIEL® (tandospirone) 2.2 2.0 (6.0) 77.9 2.7 2.6 Serotonin-agonist antianxiety drug TAGAMET® (cimetidine) 2.2 1.9 (12.6) 78.6 2.7 2.4 H2-receptor antagonist TRERIEF® (zonisamide) Therapeutic agent for Parkinson’s － 0.6 － 54.0 － 1.1 disease -supplementary4- Pharmaceuticals（Overseas） （Billions of Yen） Nine Nine Year ending months Generic name months Change (Ｂ)/(Ｃ) Year ended 3/31/10 ended ended 3/31/09 (Forecasts) Therapeutic indication 12/31/08 12/31/09 (%) (%) (C) (A) (B) meropenem trihydrate 10.7 12.8 18.8 69.0 16.2 [16.5] 18.5 Carbapenem antibiotic mosapride citrate 0.8 0.8 (2.1) 67.7 1.0 1.2 Gastroprokinetic Zonisamide 1.0 0.4 (65.1) 90.1 1.0 0.4 Antiepileptic Note: (B) and (C) include sales of Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., a Chinese subsidiary, which was newly added as a consolidated subsidiary from this fiscal year.
Load more

Recommended publications
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • Spectrofluorometric Determination of Some Β-Blockers in Tablets And
    ORIGINAL ARTICLES Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia Spectrofluorometric determination of some b-blockers in tablets and human plasma using 9,10-dimethoxyanthracene-2-sodium sulfonate H. Abdine, M. A. Sultan, M. M. Hefnawy, F. Belal Received April 16, 2004, accepted June 2, 2004 Prof. Dr. F. Belal, Department of Pharmaceutical Chemistry, College of Pharmacy, P.O.Box 2457, King Saud University, Riyadh 11451, Saudi Arabia [email protected] Pharmazie 60: 265–268 (2005) A simple and sensitive spectrofluorometric method was developed for the quantitative determination of some b-blockers, namely arotinolol, atenolol and labetalol as hydrochloride salts. The method is based on the reaction of these drugs as n-electron donors with the fluorogenic reagent 9,10-dimethoxy-2- anthracene sulfonate (DMAS) as p-acceptor in acidic medium. The obtained ion-pairs were extracted into chloroform and measured spectrofluorometrically at 452 nm after excitation at 385 nm. The fluor- escence intensity-concentration plots are rectilinear over the ranges of 0.5–5 mg Á ml1, 1.0–11.0 mg Á ml1 and 0.6–6.4 mg Á ml1 for labetalol, atenolol and arotinolol, respectively. The different parameters affect- ing the reaction pathway were thoroughly studied and optimized. No interference was observed from the common pharmaceutical excipients. The proposed method was successfully applied to the analy- sis of tablets and the results were statistically compared with those obtained by reference methods. The method was further extended to the in vitro determination of the drugs in spiked human plasma, the% recoveries (n ¼ 3) ranged from 96.98 Æ 1.55 to 98.28 Æ 2.19.
    [Show full text]
  • A Meta-Analysis of the Efficacy and Safety of Arotinolol in the Treatment of Chinese Patients with Essential Hypertension
    African Journal of Pharmacy and Pharmacology Vol. 6(1), pp. 36-42, 8 January, 2011 Available online at http://www.academicjournals.org/AJPP DOI: 10.5897/AJPP11.452 ISSN 1996-0816 ©2011 Academic Journals Full Length Research Paper A meta-analysis of the efficacy and safety of arotinolol in the treatment of Chinese patients with essential hypertension Du Bing 1# ，，，Cui Wen-peng 2# ，，，Xu Guo-liang 1, Sun Guo-qiang 1, Wu Guo-dong 1, Qu Rui 1, Lin Shu-mei 1, Liu Yun-yang 1, Qin Ling 1* 1Department of Cardiology, the second part of First Hospital, Jilin University, Changchun, China. 2Department of Nephrology, Second Hospital, Jilin University, Changchun, China. Accepted 8 September, 2011 Arotinolol had been used for treatment of essential hypertension. We conducted a meta-analysis to compare the efficacy and safety of arotinolol with other antihypertensive drugs in treating essential hypertension. Medical databases and review articles were screened with prespecified criteria for randomized controlled trials that reported the effects of and adverse reactions to arotinolol and other antihypertensive drugs in treating essential hypertension. Literature identified meta-analysed using RevMan4.2. Methodology quality of the selected studies was conducted using a Jadad scale. The results were that a total of 176 articles had been found of which 6 were finally included for meta- analysis. The meta-analysis compared the efficacy and safety of arotinolol with other common antihypertensive drugs, including enalapril, felodipine, imidapril, cilinidipine, metroprolol and atenolol. Results indicated that there were no evidence for differences in safety and efficacy. Homogeneity test, χ2 = 4.41, df = 7, P = 0.73 (efficacy); χ2 = 2.96, df = 4, P = 0.56 (safety); combined test, Z = 0.64 (P = 0.52), OR = 1.17, 95% confidence interval (CI) (0.72, 1.85) (efficacy); Z = 1.75 (P = 0.08), OR = 0.60, 95% CI (0.34, 1.06) (safety).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Essential Tremor: Diagnosis and Management BMJ: First Published As 10.1136/Bmj.L4485 on 5 August 2019
    STATE OF THE ART REVIEW Essential tremor: diagnosis and management BMJ: first published as 10.1136/bmj.l4485 on 5 August 2019. Downloaded from Vicki Shanker ABSTRACT Essential tremor is one of the most common movement disorders in adults and can Department of Neurology, Icahn School of Medicine at Mount affect both children and adults. An updated consensus statement in 2018 redefined Sinai, New York, NY 10029, USA essential tremor as an isolated action tremor present in bilateral upper extremities Correspondence to: [email protected] for at least three years. Tremor may also be present in other locations, commonly Additional material is published the neck or the vocal cords. Patients with additional neurologic symptoms are online only. To view please visit the journal online. now categorized as “essential tremor plus.” Additional clinical features associated Cite this as: BMJ 2019;366:l4485 with the condition include but are not limited to cognitive impairment, psychiatric http://dx.doi.org/10.1136/bmj.l4485 Series explanation: State of the disorders, and hearing loss. When treatment is needed, propranolol and primidone Art Reviews are commissioned are considered first line treatments. Patients who are severely affected are often on the basis of their relevance to academics and specialists offered deep brain stimulation. Although the ventral intermediate nucleus of the in the US and internationally. For this reason they are written thalamus is the traditional surgical target, the caudal zona incerta is also being predominantly by US authors. studied as a possible superior alternative. Magnetic resonance imaging guided high intensity focused ultrasound is a newer surgical alternative that may be ideal for patients with substantial medical comorbidities.
    [Show full text]
  • Infrared Reference Spectra a to B
    JP XV Infrared Reference Spectra 1373 Acebutolol Hydrochloride Preparation of sample: Potassium bromide disk method Acetaminophen Preparation of sample: Potassium bromide disk method Acetohexamide Preparation of sample: Potassium bromide disk method 1374 Infrared Reference Spectra JP XV Acetylcholine Chloride for Injection Preparation of sample: Potassium bromide disk method Aclarubicin Hydrochloride Preparation of sample: Potassium bromide disk method Acrinol Hydrate Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1375 Afloqualone Preparation of sample: Potassium bromide disk method Alacepril Preparation of sample: Potassium bromide disk method Alprenolol Hydrochloride Preparation of sample: Potassium chloride disk method 1376 Infrared Reference Spectra JP XV Alprostadil Preparation of sample: Potassium bromide disk method Amantadine Hydrochloride Preparation of sample: Potassium chloride disk method Ambenonium Chloride Preparation of sample: Potassium chloride disk method JP XV Infrared Reference Spectra 1377 Amidotrizoic Acid Preparation of sample: Potassium bromide disk method Amikacin Sulfate Preparation of sample: Potassium bromide disk method Amoxapine Preparation of sample: Potassium bromide disk method 1378 Infrared Reference Spectra JP XV Amoxicillin Hydrate Preparation of sample: Potassium bromide disk method Anhydrous Ampicillin Preparation of sample: Potassium bromide disk method Ampicillin Hydrate Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1379
    [Show full text]
  • Acebutolol Hydrochloride Acetohexamide 1 Acetohexamide 2
    JP XV Ultraviolet-visible Reference Spectra 1519 Acebutolol Hydrochloride A solution in 0.01 mol/L hydrochloric acid TS (1 in 100,000) Acetohexamide 1 A solution prepared as follows: Dissolve 0.10 g in 100 mL of methanol. To 5 mL of this solution add 20 mL of 0.5 mol/L hydrochloric acid TS and 75 mL of methanol (Sample solution 1). Acetohexamide 2 A solution prepared as follows: To 10 mL of Sample solution 1 add methanol to make 50 mL (Sample solution 2). 1520 Ultraviolet-visible Reference Spectra JP XV Aclarubicin Hydrochloride A solution in diluted methanol (4 in 5) (3 in 100,000) Acrinol Hydrate An aqueous solution (3 in 250,000) Actinomycin D A solution in methanol (3 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1521 Afloqualone A solution in ethanol (99.5) (1 in 150,000) Alimemazine Tartrate An aqueous solution (1 in 100,000) Allopurinol An aqueous solution (1 in 200,000) 1522 Ultraviolet-visible Reference Spectra JP XV Alprazolam A solution in ethanol (95) (1 in 200,000) Alprenolol Hydrochloride A solution in ethanol (95) (1 in 10,000) Alprostadil A solution prepared as follows: To 10 mL of a solution in ethanol (99.5) (1 in 100,000) add 1 mL of potassium hydroxide-ethanol TS, and allow to stand for 15 minutes. JP XV Ultraviolet-visible Reference Spectra 1523 Alprostadil Alfadex A solution prepared as follows: To 10 mL of a solution in dilute ethanol (3 in 10,000) add 1 mL of potassium hydroxide-ethanol TS, and allow to stand for 15 minutes.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Beneficial Effects of Γ-Aminobutyric Acid on Right Ventricular Pressure
    Life Sciences 91 (2012) 693–698 Contents lists available at SciVerse ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie Beneficial effects of γ-aminobutyric acid on right ventricular pressure and pulmonary vascular remodeling in experimental pulmonary hypertension Rie Suzuki a, Rumi Maehara a, Shuhei Kobuchi b, Ryosuke Tanaka a, Mamoru Ohkita a, Yasuo Matsumura a,⁎ a Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka, Japan b Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, Kobe, Hyogo, Japan article info abstract Article history: Aims: It has been reported that activation of the sympathetic nervous system and increase in plasma Received 19 October 2011 norepinephrine (NE) levels are observed in patients with pulmonary hypertension (PH). γ-Aminobutyric Accepted 4 April 2012 acid (GABA) is one of the major inhibitory neurotransmitters in the central nervous system and suppresses peripheral sympathetic neurotransmission. This study investigated whether chronic treatment with GABA Keywords: prevents the development of monocrotaline (MCT)-induced PH. To elucidate the relationship between Monocrotaline the development of PH and sympathetic nerve activity, hemodynamic parameters, cardiac functions, and Pulmonary hypertension γ-Aminobutyric acid plasma NE concentrations as well as cardiac endothelin-1 (ET-1) contents of MCT-induced PH rats were Norepinephrine evaluated with or without GABA treatment. Sympathetic nervous system Main methods: Rats were injected with MCT (60 mg/kg) or saline subcutaneously and these rats were Endothelin-1 randomly divided into GABA (500 mg/kg/day for 4 weeks)- or vehicle-treated groups, respectively. Key finding: MCT-treated rats had higher right ventricular systolic pressures, right ventricle-to-left ventricle plus septum weight ratios, pulmonary arterial medial thickening, and plasma NE levels than those of saline-injected rats.
    [Show full text]
  • The Advantages of Carvedilol in Coronary Artery Disease
    FACTA UNIVERSITATIS Series: Medicine and Biology Vol.8, No 1, 2001, pp. 11 - 18 UC 612.17; 611.12 THE ADVANTAGES OF CARVEDILOL IN CORONARY ARTERY DISEASE Svetlana Apostolović¹, Milan Pavlović¹, Miloje Tomašević¹, Aleksandar Stojković¹, Ružica Janković¹, Slobodan Ilić² ¹Clinic for Cardiology, Clinical Center, Niš, Yugoslavia, ²Society for Liason Psychiatry, Niš, Yugoslavia E-mail: [email protected] Summary. Dilatrend (carvedilol) is a nonselective beta and alpha blocker with antioxidation and antiprolipherative effects. These effects prevent mechanical damage of the endothelium of coronary arteries and have no negative influ- ence on metabolic risk factors: lipid prophyl and insulin resistence. With beta-blockade, dilatrend (carvedilol) reduces the heart rate and blood pressure, with alpha-blockade it reduces the peripheral vascular resistence and in that way decreases the myocardial oxygen consumption and myocardial wall stress. Dilatrend (carvedilol) prolonges exercise limits (duration of exercise). Applied in the acute phase of myocardial infarction, dilatrend (carvedilol) increases the patients' survival rate, reduces new coronary events, and with antioxydation action it prevents reperfusion arrhyth- mias. With positive hymodinamic effects it improves the left ventricle function in patients with ischemic cardiomyopa- thy, and gives a chance for survival to the coronary patients who run high surgery risk. Key words: Carvedilol, coronary disease, myocardial infarction The effect of carvedilol we strive to maintain the function and the integrity of upon the coronary arteries endothelium the endothelium of coronary arteries, primarily by controling the variable risk factors. Today, by using a The central position in the onset and the determina- particular drug it is possible to influence most of the tion of the course of the coronary disease is occupied by mentioned processes that lead to the damage of the the atherosclerotic plaque of the coronary artery.
    [Show full text]
  • Reporting and Learning System for Medication Errors: the Role Of
    REPORTING AND LEARNING SYSTEMS FOR MEDICATION ErrORS: THE ROLE OF PHARMACOVIGILANCE CENTRES Reporting and learning systems for medication errors: the role of pharmacovigilance centres WHO Library Cataloguing-in-Publication Data Reporting and learning systems for medication errors: the role of pharmacovigilance centres. 1.Medication Errors – prevention and control. 2.Pharmacovigilance. 3.Drug Monitoring. I.World Health Organization. ISBN 978 92 4 150794 3 (NLM classification: QV 771) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publica- tions – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization con- cerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent ap- proximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Predicting Interactions of Antihypertensive Drugs and Rifampin in Tuberculosis Patients Using BDDCS Tingting Yan1,2#, Wei Liu1,3#, Ken Chen1,2, Li Yang1,3, Leslie Z
    Predicting interactions of antihypertensive drugs and rifampin in tuberculosis patients using BDDCS Tingting Yan1,2#, Wei Liu1,3#, Ken Chen1,2, Li Yang1,3, Leslie Z. Benet1,4*, Suodi Zhai1,3* 1 Pharmacy Department, Peking University Third Hospital, Beijing 100191, China; 2 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; 3 Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center, Beijing 100191 China; 4 University of California San Francisco, San Francisco, 94143, United States #Tingting Yan and Wei Liu contributed equally to this work. *Corresponding author at: Peking University Third Hospital, No. 49 North Garden Rd, Haidian District, Beijing 100191, China (Suodi Zhai); University of California San Francisco, 533 Parnassus Avenue, Room U-68, San Francisco, CA 94143- 0912, USA (Leslie Z. Benet). Tel: 8610-82266686 (Suodi Zhai); (415) 476-3853 (Leslie Z. Benet) Fax: 8610-82266686 (Suodi Zhai); (415) 476-8887 (Leslie Z. Benet) E-mail: [email protected] (Suodi Zhai); [email protected] (Leslie Z. Benet) Running Head: Predicting interactions of antihypertensive drugs and rifampin in tuberculosis patients using BDDCS 1 Abstract Background Lack of blood pressure control is often seen in hypertensive patients concomitantly taking antituberculosis (TB) medications due to the complex drug-drug interactions between rifampin and antihypertensive drugs. Therefore, it is of clinical importance to understand the mechanism of interactions between rifampin and antihypertensive drugs, thereby allowing predictions and recommendations on the use of antihypertensive drugs in such co-medicated patients. Objective To predict interactions between antihypertensive drugs and rifampin under the theory of the Biopharmaceutics Drug Disposition Classification System (BDDCS), taking into consideration the role of drug transporter and metabolic enzyme interactions, and to give guidance on the selection of antihypertensive drugs for patients with TB.
    [Show full text]